There is a great urgency of detecting and monitoring myocardial fibrosis in clinical practice with the aim to improve and personalize therapy against cardiac remodelling. Hence, the aim of this study was to describe alterations in and show potential correlations between the structural characteristics and the molecular and biochemical markers of cardiac remodelling on a model of isoproterenol-induced heart failure. Two groups of 3-month-old male Wistar rats (n = 8 per group) were sacrificed after four weeks of treatment: control (placebo), ISO (5 mg/kg/day intraperitoneally). Chronic ISO treatment led to heart failure (HF) characterized by significant reduction of systolic blood pressure (SBP) accompanied by an increase in left ventricular weight (LVW) along with increased collagen content in the LV. The collagen content correlated negatively with SBP (R = -0.776, P < 0.001) and positively with LVW (R = 0.796, P < 0.001), with Col1a1 (0.83; P < 0.001) and Acta2 (0.73; P < 0.01). Moreover, the mRNA expression of fibrotic remodelling indicator, i.e. TGF-β1 tended to increase, while the level of fibrinolysis markers (MCP-1, TIMP-2, MMP) were unchanged. The plasma markers of collagen, procollagen I C-terminal propeptide (PICP) was 37.34 ± 7.10 pg/mL in control and was reduced by 42% (P < 0.05) in the ISO group and procollagen III N-terminal propeptide (PIIINP) was 1216.7 ± 191.0 pg/mL in control and was decreased by 66% (P < 0.05) in the ISO group. Surprisingly, there was no positive correlation between plasma markers of collagen, i.e. PICP and PIIINP and collagen content or molecular markers of collagen. However, both PICP and PIIINP correlated with BW (R = 0.712, resp. 0.803, P < 0.001), which was significantly reduced (by 25%, P < 0.05) in the ISO group. In conclusion, we assume that the collagen content of the left ventricle does not need unavoidably correlate with plasma markers of collagen, which might be affected by confounding factors in heart failure, such as loss of body weight, presumably associated with a catabolic condition.

• MeSH
• isoprenalin MeSH
• kolagen metabolismus   MeSH
• krevní tlak MeSH
• peptidové fragmenty krev   MeSH
• potkani Wistar MeSH
• prokolagen krev   MeSH
• remodelace komor * MeSH
• srdeční komory metabolismus   MeSH
• srdeční selhání chemicky indukované   metabolismus   patofyziologie   MeSH
• zvířata MeSH
• Check Tag
• mužské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH

Cardiovascular diseases including hypertension are often associated with behavioural alterations. The aim of this study was to show, whether ivabradine, the blocker of If-channel in sinoatrial node, is able to modify the behaviour of rats in L-nitro-arginine methyl ester (L-NAME)-induced hypertension and to compare the effect of ivabradine with captopril and melatonin. 12-week-old male Wistar rats were divided into the following groups: controls, ivabradine (10 mg/kg/24 h), L-NAME (40 mg/kg/24 h), L-NAME + ivabradine, L-NAME + captopril (100 mg/kg/24 h), L-NAME + melatonin (10 mg/kg/24 h). Systolic blood pressure (SBP) and heart rate (HR) were measured by tail-cuff method once a week. The behaviour of rats was investigated during 23-hours in the phenotyper after four weeks of the treatment. Chronic administration of L-NAME induced hypertension without a change in HR. All tested substances partly prevented the increase of SBP, while ivabradine and melatonin also reduced HR. Ivabradine, captopril and melatonin reduced daily food intake, slightly decreased daily water intake and attenuated body weight gain. In L-NAME group, locomotor activity was enhanced by ivabradine, whereas exploratory behaviour was increased by melatonin and captopril. In conclusion, ivabradine, besides its potentially protective hemodynamic actions, does not seem to exert any disturbing effects on behaviour in L-NAME-induced hypertension in rats, while some of its effects were similar to captopril or melatonin. It is suggested that ivabradine used in cardiovascular indications is harmless regarding the effect on behaviour.

• MeSH
• antihypertenziva farmakologie   MeSH
• benzazepiny farmakologie   MeSH
• chování zvířat účinky léků   MeSH
• hypertenze farmakoterapie   metabolismus   MeSH
• inhibitory ACE farmakologie   MeSH
• kaptopril farmakologie   MeSH
• krevní tlak účinky léků   MeSH
• krysa rodu rattus MeSH
• lokomoce účinky léků   MeSH
• melatonin farmakologie   MeSH
• NG-nitroargininmethylester metabolismus   MeSH
• oxid dusnatý metabolismus   MeSH
• potkani Wistar MeSH
• srdeční frekvence účinky léků   MeSH
• synthasa oxidu dusnatého metabolismus   MeSH
• zvířata MeSH
• Check Tag
• krysa rodu rattus MeSH
• mužské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH

OBJECTIVE: Doxorubicin is a recognized chemotherapeutic agent widely employed in human malignancies. The limiting factor of its use is a number of side effects. The aim of this work was to show, whether administration of doxorubicin could induce behavioral disturbances in rats, and whether angiotensin-converting enzyme inhibitor captopril or melatonin can modify these potential alterations. DESIGN AND METHODS: Four groups of 3-month-old Wistar rats (twelve per group) were treated for 4 weeks: control (placebo-treated), doxorubicin (DOX) (5mg/kg i.v. in a single intravenous dose), DOX rats treated with either melatonin (10mg/kg/24h) or captopril (100mg/kg/24h). Systolic blood pressure (SBP) and the level of oxidative stress were investigated and behavioral tests of anxiety-open field test (OF), elevated plus maze (EPM) and light-dark box (LDB) were accomplished. RESULTS: Doxorubicin increased significantly systolic blood pressure and parameters of oxidative stress. Moreover, doxorubicin enhanced the level of anxiety in the tests of OF, EPM, and LDB. Captopril and melatonin prevented the blood pressure rise and the enhancement of oxidative load. Importantly, both substances reduced the parameters of anxiety. CONCLUSION: Chronic administration of captopril or melatonin has shown anxiolytic effect in the model of doxorubicin-induced anxiety. It does not seem unreasonable to suppose that this protective effect of captopril or melatonin against anxiety development might have been related to the antioxidative effects of both substances.

• MeSH
• antagonismus léků MeSH
• biologické markery metabolismus   MeSH
• chování zvířat účinky léků   MeSH
• doxorubicin farmakologie   MeSH
• kaptopril farmakologie   MeSH
• krevní tlak účinky léků   MeSH
• krysa rodu rattus MeSH
• melatonin farmakologie   MeSH
• oxidační stres účinky léků   MeSH
• potkani Wistar MeSH
• protinádorová antibiotika farmakologie   MeSH
• zvířata MeSH
• Check Tag
• krysa rodu rattus MeSH
• mužské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH

The multimarker approach using Luminex technology represents a new tool for studying the pathogenesis of cardiovascular disease. Although many cardiac biomarkers in heart failure have been well established, the role and significance of their measurement in hypertensive patients is still questionable. The aim of our study was to evaluate the relationship of selected biomarkers in L-NAME-induced hypertension to the left ventricular remodeling in the two different periods of hypertension development. Four groups of 3-month-old male Wistar rats were investigated: (1) control 4 (placebo for 4 weeks), (2) control 7 (placebo for 7 weeks), (3) L-NAME 4 (40 mg/kg/day for 4 weeks), and (4) L-NAME 7 (40 mg/kg/day for 7 weeks). BNP, cTnI, TNF-α, and VEGF were measured using Rat CVD Panel 1 Kit (Milliplex® MAP). Cardiac troponin T was determined using Elecsys® Troponin T high sensitive immunoassay (Roche, Switzerland). Although the systolic blood pressure increases about 50% in L-NAME-induced hypertension in rat, both hypertrophy and fibrosis were expressed only slightly in this experiment. The levels of BNP, TNF-α, or VEGF did not differ significantly among groups. However, cardiac troponin T measured by high sensitive ELISA was significantly (P<0.05) increased in L-NAME 4 (0.229 μg/l versus 0.034 μg/l) and L-NAME-7 groups (0.366 μg/l versus 0.06 μg/l) in comparison with the controls. We conclude that the slightly increased cTnT levels could indicate ischemic damage of L-NAME-hypertensive heart. Importantly, to our best knowledge, this is the first study indicating that CVD rat panel may be a useful methodological tool in experimental cardiology.

• MeSH
• biologické markery krev   MeSH
• hypertenze krev   chemicky indukované   patofyziologie   MeSH
• imunoanalýza MeSH
• inhibitory enzymů MeSH
• krevní tlak účinky léků   MeSH
• krysa rodu rattus MeSH
• natriuretický peptid typu B krev   MeSH
• NG-nitroargininmethylester MeSH
• potkani Wistar MeSH
• synthasa oxidu dusnatého antagonisté a inhibitory   MeSH
• TNF-alfa krev   MeSH
• troponin I krev   MeSH
• troponin T krev   MeSH
• vaskulární endoteliální růstový faktor A krev   MeSH
• zvířata MeSH
• Check Tag
• krysa rodu rattus MeSH
• mužské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH

• MeSH
• antioxidancia farmakokinetika   terapeutické užití   MeSH
• finanční podpora výzkumu jako téma MeSH
• hypertenze MeSH
• kardiovaskulární nemoci chemicky indukované   metabolismus   MeSH
• modely u zvířat MeSH
• NG-nitroargininmethylester MeSH
• reaktivní formy kyslíku škodlivé účinky   MeSH
• synthasa oxidu dusnatého biosyntéza   účinky léků   MeSH
• Publikační typ
• srovnávací studie MeSH

• MeSH
• cévy anatomie a histologie   patofyziologie   účinky léků   MeSH
• finanční podpora výzkumu jako téma MeSH
• hypertenze etiologie   genetika   MeSH
• krevní tlak genetika   imunologie   MeSH
• NG-nitroargininmethylester metabolismus   MeSH
• potkani Wistar anatomie a histologie   fyziologie   genetika   MeSH
• synthasa oxidu dusnatého biosyntéza   MeSH
• zvířata MeSH
• Check Tag
• zvířata MeSH
• Publikační typ
• srovnávací studie MeSH

• MeSH
• finanční podpora výzkumu jako téma MeSH
• zvířata MeSH
• Check Tag
• zvířata MeSH
• Publikační typ
• srovnávací studie MeSH

• MeSH
• aorta thoracica účinky léků   MeSH
• finanční podpora výzkumu jako téma MeSH
• hypertenze diagnóza   MeSH
• krevní tlak účinky záření   MeSH
• melatonin farmakologie   MeSH
• modely nemocí na zvířatech MeSH
• NG-nitroargininmethylester farmakologie   MeSH
• oxid dusnatý nedostatek   MeSH
• potkani inbrední SHR MeSH
• zvířata MeSH
• Check Tag
• zvířata MeSH
• Publikační typ
• srovnávací studie MeSH

• MeSH
• antihypertenziva farmakologie   terapeutické užití   MeSH
• exprese genu účinky léků   MeSH
• finanční podpora výzkumu jako téma MeSH
• hypertenze farmakoterapie   MeSH
• krevní tlak účinky záření   MeSH
• melatonin farmakologie   terapeutické užití   MeSH
• NF-kappa B chemie   MeSH
• potkani inbrední SHR MeSH
• reaktivní formy kyslíku chemie   MeSH
• spironolakton farmakologie   terapeutické užití   MeSH
• synthasa oxidu dusnatého chemie   účinky léků   MeSH
• zvířata MeSH
• Check Tag
• zvířata MeSH
• Publikační typ
• srovnávací studie MeSH

• MeSH
• aorta cytologie   metabolismus   účinky léků   MeSH
• finanční podpora výzkumu jako téma MeSH
• hypertriglyceridemie genetika   metabolismus   MeSH
• inhibitory ACE metabolismus   MeSH
• kaptopril metabolismus   MeSH
• proteiny analýza   MeSH
• remodelace komor fyziologie   MeSH
• srdeční komory cytologie   chirurgie   mikrobiologie   MeSH
• techniky in vitro MeSH
• zvířata MeSH
• Check Tag
• mužské pohlaví MeSH
• zvířata MeSH